China agreed to set up a system to resolve conflicts over drug patents, a move that may help U.S. pharmaceutical companies seeking greater protections for their branded medicine in developing nations.
The changes, which take key provisions from an American law on the books for more than three decades, were included in the text of what U.S. and Chinese officials billed as the first phase of a broader trade pact. President Donald Trump held a signing ceremony for the deal at the White House Wednesday.
Read the full text of the agreement here
Under terms of the deal, patent disputes ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.